Vivos Therapeutics (VVOS) Capital Leases (2025 - 2026)

Vivos Therapeutics' (VVOS) quarterly Capital Leases came in at $98000.0 in Q1 2026, down 13.27% on a QoQ basis from $113000.0 in Q4 2025.

Vivos Therapeutics (VVOS) Capital Leases (2025 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 2 years of Capital Leases data on file, last reported at $98000.0 in Q1 2026.

On a quarterly basis, Capital Leases changed N/A year-over-year to $98000.0 in Q1 2026; TTM through Mar 2026 was $98000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $113000.0, changed N/A from the prior year.
Capital Leases for Q1 2026 stood at $98000.0, down from $113000.0 in the prior quarter.
Over the last five years, Capital Leases for VVOS reached as high as $141000.0 in Q2 2025 and fell as low as $98000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Vivos Therapeutics	3.62 Mn	1.38 Mn	3.06 Mn

Download Data